Parikh Sanam

Director Parikh Sanam purchased 1,000 shares of THAR at $1.45; stock down 69.0% from 52-week high, company unprofitable ($-2.5M net income).

Parikh Sanam, a Director, purchased 1,000 shares at $1.45 on 2025-06-20, increasing his holdings by 129.9% to 1,770 shares. The stock is trading 69.0% below its 52-week high and down 10.3% over the past 90 days, creating a significantly depressed price environment. Tharimmune reported negative net income of $-2.5M on a $3.5M market cap, indicating the company is unprofitable. A cluster pattern is present, with 2 other insiders also buying within the past 14 days, suggesting potential coordinated confidence at these price levels. However, the insider's prior buy at THAR on 2025-05-15 showed a -0.8% 30-day return, and his broader track record across all tickers (1 prior buy) also averaged -0.8% 30-day returns, indicating that his recent purchase decisions have not yet translated into positive stock performance.

Director Sanam Parikh opens new position: 770 shares of THAR at $1.30 (now $1.33, -77.3% from 52-week high)

Director Sanam Parikh purchased 770 shares at $1.30 on 2025-05-15, establishing an initial position in Tharimmune, Inc. The company is unprofitable with net income of $-2,541,704.00 and a market cap of $3,538,766.91. At $1.33 current price, the stock trades -77.3% from its 52-week high of $5.86 but has recovered 20.9% over the past 30 days after a 90-day decline of -30.0%. This small open-market purchase by a director in a micro-cap biotech with ongoing losses occurs against a backdrop of severe valuation compression and volatile price action, warranting review of the underlying business trajectory.